Glutathione and drug resistance

Cancer Investigation

Volumn 14, Issue 2, 1996, Pages 158-168

  Schröder, Carolina P ^a   Godwin, Andrew K ^a   O'Dwyer, Peter J ^a   Tew, Kenneth D ^a   Hamilton, Thomas C ^a   Ozols, Robert F ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GLUTATHIONE; MELPHALAN; MITOMYCIN C;

CANCER; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW;

EID: 0029944498     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909609018891     Document Type: Review

References (122)

1. Rosenberg B: Fundamental studies with cisplatin. Cancer 55: 2303-2316, 1985.
2. Perez RP, Hamilton TC, Ozols RF: Resistance to alkylating agents and cisplatin: Insights from ovarian carcinoma model systems. Pharmacol Ther 48:19-27, 1990.
3. Hamilton TC: Common epithelial tumors of the ovary. Part I: Biology. Curr Probl Cancer 16:4-57, 1992.
4. Hospers GAP, Mulder NH, de Vries EGE: Mechanisms of cellular resistance to cisplatin. Med Oncol Tumor Pharmacother 5:145-151, 1988.
5. Andrews PA, Howell SB: Cellular pharmacology of cisplatin: Perspectives on mechanisms of acquired resistance. Cancer Cells 2:35-43, 1990.
6. Hayes JD, Wolf CR: Molecular mechanisms of drug resistance. Biochem J 272:281-295, 1990.
7. deGraeff A, Slebos RJC, Rodenhuis S: Resistance to cisplatin and analogues: Mechanisms and potential clinical implications. Cancer Chemother Pharmacol 22:325-332, 1988.
8. Fojo A, Hamilton TC, Young RC, et al: Multidrug resistance in ovarian cancer. Cancer 60:2075-2080, 1987.
9. Byfield J, Calabro-Jones P: Carrier dependent and carrier independent transport of anticancer alkylating agents. Nature 294:281-283, 1981.
10. Vistica D: Cytotoxicity as an indicator for transport mechanism: Evidence that melphalan is transported by two leucine-preferring carrier systems in the L1210 murine leukemia cell. Biochim Biophys Acta 550:309-317, 1979.
11. Begleiter A, Grover J, Froese E, et al: Membrane transport, sulfhydryl levels and DNA cross linking in Chinese hamster ovary cells, sensitive and resistant to melphalan. Biochem Pharmacol 32:293-300, 1983.
12. Green J, Vistica D, Young RC, et al: Potentiation of melphalan Cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res 44:5427-5431, 1984.
13. Parker RJ, Eastman A, Bostick-Bruton F, et al: Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 87:772-777, 1991.
14. Andrews PA, Velury S, Mann SC, et al: cis-Diamminedichloroplalinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 48:68-73, 1988.
15. Mann SC, Andrews PA, Howell SB: Short-term cis-diainminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 25:236-240, 1990.
16. Kuppen PJK, Schuitemaker H, van't Veer LJ, et al: cis-Diamminedichloroplatinum (II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res 48:3355-3359, 1988.
17. Chu G: Cellular responses to cisplatin. J Biol Chem 269(2):787-790, 1994.
18. Kawai K, Kamatani N, Georges E, et al: Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminedichloroplatinum (II). J Biol Chem 265(22):13137-13142, 1990.
19. Bernal SD, Speak JA, Boeheim K, et al: Reduced membrane protein associated with resistance of human squamous carcinoma cells to methotrexate and cis-platinum. Mol Cell Biochem 95:61-70, 1990.
20. Ozols RF, Hamilton TC, Masuda H, et al: Manipulation of cellular thiols to influence drug resistance. In: Mechanisms of Drug Resistance in Neoplastic Cells, edited by PV Wooley III, KD Tew, San Diego CA, Academic Press, 1989, pp 289-306.
21. Hamilton TC, Lai G-M, Rothenberg ML, et al: Mechanisms of resistance to cisplatin and alkylating agents. Int Drug Resistance in Cancer Therapy, edited by RF Ozols, Boston, Kluwer Academic Publishers, 1989, pp 151-170.
22. Masoda H, Ozols RF, Lai G-M, et al: Increased DNA repair as a mechanism of acquired resistance to cis- diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 48:5713-5716, 1988.
23. Eastman A, Schulte N: Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum (II). Biochemistry 27: 4730-4734, 1988.
24. Eastman A, Gorman T, Ostrom K: Cisplatin resistance and enhanced DNA repair. Proc Am Assoc Cancer Res 33:174, 1992.
25. Johnson SW, Perez RP, Godwin AK, et al: Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol 47:689-697, 1994.
26. Lai G-M, Ozols RF, Smyth JF, et al: Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol 37:4597-4600, 1988.
27. Lai G-M, Ozols RF, Hamilton TC: Role of glutathione on DNA repair in cisplatin resistant human ovarian cancer cell lines. J Natl Cancer Inst 81:535-539, 1989.
28. Zhen W, Link CJ, O'Connor PM, et al: Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 3689-3698, 1991.
29. Katz EJ, Andrews PA, Howell SB: The effect of DNA polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells. Cancer Commun 2(4):159-164, 1990.
30. Masuda I, Tanaka T, Matsuda H, et al: Increased removal of DNA-bound platinum in human ovarian cancer line resistant to cis-diamminedichloroplatinum (II). Cancer Res 50:1863-1866, 1990.
31. Geleziunas R, McQuillan A, Malapetsa A, et al: Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustards. J Natl Cancer Inst 83:557-564, 1991.
32. Dabholkar M, Bostick-Bruton F, Weber C, et al: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84:1512-1517, 1992.
33. Bohr VA, Smith CA, Okumoto DS, et al: DNA repair in an active gene: Removal of pyrimidine dimers from the DHFR gene of CHO cells is much more efficient than the genome overall. Cell 40:359-369, 1985.
34. Bohr VA, Okumoto DS, Ho L, et al: Characterization of a DNA repair domain containing the DHFR gene in CHO cells. J Biol Chem 261:16666-16672, 1986.
35. Okumoto DS, Bohr VA: DNA repair in the metallothionein gene increases with transcriptional activation. Nucleic Acids Res 15:10021-10030, 1987.
36. 2 phase and cell death induced by cisplatin. J Natl Cancer Inst 82:749-755, 1990.
37. Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 40:2353-2362, 1990.
38. Eastman A: Activation of programmed cell death by anticancer agents: Cisplatin as a model system. Cancer Cells 2:275-280, 1990.
39. Hamer D: Metallothionein. Annu Rev Biochem 55:913-951, 1986.
40. Kelley SL, Basu A, Teicher BA, et al: Overexpression of metallothionein confers resistance to anticancer drugs. Science 241:1813-1815, 1988.
41. Kasahara K, Fujiwara Y, Nishio K, et al: Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 51:3237-3242, 1988.
42. Schilder RJ, Hall L, Monks A, et al: Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer 45:416-422, 1990.
43. Andrews PA, Murphy MP, Howell SB: Metallothionein-mediated cisplatin resistance in human ovarian cancer cells. Cancer Chemother Pharmacol 19:149-154, 1987.
44. Meijer C, Mulder NH, Groten JP, et al: The role of various sulfhydryl compounds, among which glutathione and metallothionein, in differential cisplatin sensitivity of human testicular cancer as compared to colon cancer cell lines. Proc Am Assoc Cancer Res 35:389, 1994.
45. Lohrer H, Robson T: Overexpression of metallothionein in CHO cells and its effect in cell killing by ionizing radiation and alkylating agents. Carcinogenesis 10:2279-2284, 1989.
46. Murphy D, McGown AT, Crowther D, et al: Metallothionein levels in ovarian tumours before and after chemotherapy. Br J Cancer 63:711-714, 1991.
47. Macarak EJ, Kumor K, Weisz PB: Enzymatic conjugation of chlorambucil with human glutathione S-transferases and inhibition by ethacrynic acid. Biochem Pharmacol 42:1504-1507, 1991.
48. Hoskin LK, Whelan RDH, Shellard SA, et al: An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumour agents shown by a range of human tumour cell lines. Biochem Pharmacol 40:1833-1842, 1991.
49. Mistry P, Kelland LR, Sidhar AS, et al: The relationships between glutathione, glutathione S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 64:215-220, 1991.
50. Godwin AK, Meister A, O'Dwyer PJ, et al: High resistance to cisplatin in human ovarian cancer cells is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89: 3070-3074, 1992.
51. Hamilton TC, Winker MA, Louie KG, et al: Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian cancer cell lines by buthionine mediated glutathione depletion. Biochem Pharmacol 34:2583-2586, 1985.
52. Louie KG, Behrens BC, Kinsella TJ, et al: Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res 45:2110-2115, 1985.
53. Ozois RF, Louie KG, Plowman J, et al: Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem Pharmacol 36:147-153, 1987.
54. Hamaguchi K, Godwin AK, Yakushiji M, et al: Cross resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 21:5225-5233, 1993.
55. Britten RA, Green JA, Warenius HM: Cellular glutathione (GSH) and glutathione S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents. Int J Radium Oncol Biol 24:527-531, 1992.
56. Huang C-S, Chang L-S, Anderson ME, et al: Catalytic and regulatory properties of the heavy subunit of rat kidney γ-glutamyl-synthetase. J Biol Chem 268:19675-19680, 1993.
57. Meister A, Anderson ME: Glutathione. Annu Rev Biochem 52: 711-760, 1983.
58. Tew KD: Glutathione associated enzymes in anticancer drug resistance. Perspectives in Cancer Research. Cancer Res 54:4313-4320, 1994.
59. Bailey HH, Gipp JJ, Ripple M, et al: Increase in γ-glutamylcysteine synthetase activity and steady state messenger RNA levels in melphalan resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels. Cancer Res 52:5115-5118, 1992.
60. Doroshow JH, Akman S, Chu F-F, et al: Role of the glutathione peroxidase cycle in the cytotoxicity of the anticancer guinones. Pharmacol Ther 47:359-370, 1990.
61. Ranganathan S, Walsh ES, Godwin AK, et al: Cloning, sequencing and expression of human colon glyoxalase-I. J Biol Chem 268: 5661-5667, 1993.
62. Ranganathan S, Walsh ES, Tew KD: Function of glyoxalase-I, a glutathione binding protein in drug detoxification; studies using a glyoxalase-I transfectant cell line. Proc Am Assoc Cancer Res 35:377, 1994.
63. Ishikawa T, Ali-Osman F: Glutathione-associated cis- diamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells. J Biol Chem 268:20116-20125, 1993.
64. Eastman A: Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes. Chem Biol Interact 61:241-248, 1987.
65. Jakoby WB: The glutathione S-transferases: A group of multifunctional detoxification proteins. Adv Enzymol 46:383-414, 1978.
66. Mannervik B: The isoenzymes of glutathione transferase. Adv Enzymol 57:353-417, 1985.
67. Mannervik B, Danielson UH: Glutathione transferases - Structure and catalytic activity. CRC Crit Rev Biochem 23:283-337, 1988.
68. Ishikawa T: The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci 17:463-468, 1992.
69. Mannervik B, Awasthi YC, Board PG, et al: Nomenclature for human glutathione transferases. Biochem J 282:305-306, 1992.
70. Morgenstern R, DePierre JW: Membrane-bound glutathione transferases. In: Glutathione Conjugation: Mechanisms and Biological Significance, edited by H Sies, B Ketterer, New York, Academic Press, 1988, pp 157-174.
71. Meyer DJ, Coles B, Pemble SE, et al: Theta, a new class of glutathione transferases purified from rat and man. Biochem J 274:409-414, 1989.
72. Tew KD, Clapper ML, Greenberg RE, et al: Glutathione S-transferases in human prostate. Biochim Biophys Acta 926:8-15, 1987.
73. Ranganathan S, Tew KD: Immunohistochemical localization of glutathione S transferases a, m and p in normal tissue and carcinomas from human colon. Carcinogenesis 12:2383-2387, 1991.
74. Schisselbauer JC, Silber R, Papadopoulos E, et al: Characterization of glutathione S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients. Cancer Res 50:3562-3568, 1990.
75. Wang AL, Tew KD: Increased glutathione S-transferase activity in a cell line with acquired resistance to nitrogen mustards. Cancer Treat 69:677-682, 1985.
76. Evans CG, Bodell WJ, Tokuda K, et al: Glutathione and related enzymes in rat brain tumor cell resistance to 1,3(2-chloroethyI)-I-nitrosourea and nitrogen mustards. Cancer Res 47:2525-2530, 1987.
77. Robson CN, Lewis AD, Wolf CR, et al: Reduced levels of drug-induced DNA cross-linking in nitrogen mustard-resistant Chinese hamster ovary cells expressing elevated glutathione S-transferase activity. Cancer Res 47:6022-6027, 1987.
78. McGowan AT, Fox BW: A proposed mechanism of resistance to cyclophosphamide and phosphoramide mustard in a Yoshida cell line in vitro. Cancer Chemother Clin Pharmacol 17:223-226, 1986.
79. Lewis AD, Hayes JD, Wolf CR: Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: Intrinsic differences and cell cycle effects. Carcinogenesis 9:1283-1287, 1988.
80. Van der Zee AGJ, Van Ommen B, Meijer C, et al: Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy. Br J Cancer 66:930-936, 1992.
81. Morrow CS, Cowan KH: Antineoplastic drug resistance and breast cancer. Ann NY Acad Sci 698:289-312, 1993.
82. Schecter RL, Aloui-Jamali MA, Woo A, et al: Expression of rat glutathione S-transferase complementary DNA in rat mammary carcinoma cells: Impact upon alkylator-induced toxicity. Cancer Res 53:4900-4906, 1993.
83. Miyazaki M, Kohno K, Saburi Y, et al: Drug resistance to cis-diamminedichloroplatinum (II) in Chinese hamster ovary cell lines transfected with glutathione S-transferase pi gene. Biochem Biophys Res Commun 166:1358-1364, 1990.
84. Bolton MG, Hilton J, Robertson KD, et al: Kinetic analysis of the reaction of melphalan with water, phosphate, and glutathione. Drug Metab Dispos 21:986-996, 1993.
85. Awasthi S, Bajpai KK, Frenkel EP: The role of GST in melphalan-GSH interactions. Proc Am Assoc Cancer Res 35:377, 1994.
86. Tew KD, Houghton JA, Houghton PJ: Preclinical and Clinical Modulation of Anticancer Drugs, Boca Raton, FL, CRC Press, 1993.
87. Mannervik B: The isoenzymes of glutathione transferase. Adv Enzymol Relat Areas Mol Biol 58:357-417, 1985.
88. Endicott JA, Ling V: The biochemistry of P-glycoprotein- mediated multidrug resistance. Annu Rev Biochem 58:137-171, 1989.
89. Muller M, Meijer C, Zaman G, Birst P, Scheper R, Mulder N, de Vries E, Jansen P: Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 91:13033-13037, 1994.
90. Ishikawa T, Ah-Osman F: Glutathione-associated cis-diamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells J Biol Chem 268:20116-20125, 1993.
91. Bohr V, Phillips D, Hanawalt P: Heterogenaus DNA damage and repair in the human genome. Cancer Res 47:6426-6436, 1987.
92. Friedberg E: The molecular biology of micleotide excision repair of DNA: Recent progress. J Cell Sci 6(Suppl):1-23, 1987.
93. Sancar A, Sancar G: DNA repair enzymes. Annu Rev Biochem 57:29-67, 1987.
94. Ali-Osman F: Quenching of DNA cross-link precursors of chloroethylnitrosoureas and attenuation of DNA interstrand cross-linking by glutathione. Cancer Res 49:5258-5261, 1989.
95. Sharma M, He Q-Y, Tomasz M: Effects of glutathione on alkylation and cross-linking of DNA by mitomycin C: Isolation of a ternary glutathione-mitomycin-DNA adduct. Proc Am Assoc Cancer Res 35:377, 1994.
96. Olenick N, Xue L, Friedman L, et al: Inhibition of radiation-induced DNA-protein cross link repair by glutathione depletion with L-buthionine sulfoximine. Natl Cancer Inst Monogr 6:225-229, 1988.
97. Edgren R, Revesz L, Larsson A: Induction and repair of single strand DNA breaks after X-irradiation of human fibroblasts deficient in glutathione. Int J Radiat Biol 40:355-363, 1981.
98. Lai G, Ozols RF, Young RC, et al: Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J Natl Cancer Inst 81:535-539, 1989.
99. Bellamo G, Vairetti M, Stivala L, et al: Demonstration of nuclear compartmentalization of glutathione in hepatocytes. Proc Natl Acad Sei USA 89:4412-4416, 1992.
100. Crowl CV, Mastro AM, Grove DS, et al: Oxalyl thiolesters inhibit proliferation and apoptosis. Proc Am Assoc Cancer Res 35:28, 1994.
101. Griffith OW, Meister A: Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 254:7558-7560, 1979.
102. Meister A: Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol Ther 51:155-164, 1991.
103. Green JA, Vistica D, Young RC, et al: Melphalan resistance in human ovarian cancer: Characterization of drug resistant cell lines and potentiation of melphalan cytotoxicity by glutathione depletion. Cancer Res 44:5427-5431, 1984.
104. Batist G, Behrens BC, Makuch R, et al: Serial determination of glutathione levels and glutathione related enzyme activities in human tumor cells in vitro. Biochem Pharmacol 35:2257-2259, 1986.
105. Behrens BC, Hamilton TC, Grotzinger KR, et al: Characterization of a cisplatin-resistant human ovarian cancer cell line and its use in evaluation of cisplatin analogs. Cancer Res 47:414-418, 1987.
106. Meijer C, Mulder NH, Hospers GAP, et al: The role of glutathione in resistance to cisplatin in a human small cell lung carcinoma. Br J Cancer 62:72-77, 1990.
107. Barranco SC, Townsend CM, Weintraub B, et al: Changes in glutathione content and resistance to anticancer agents in human stomach cancer cells induced by treatments with melphalan in vitro. Cancer Res 50:3614-1618, 1990.
108. Lee FYF, Siemann DW, Sutherland RM: Changes in cellular glutathione content during adriamycin treatment in human ovarian cancer - A possible indictor of chemosensitivity. Int J Cancer 60:291-298, 1989.
109. Teicher BA, Holden SA, Herman TS, et al: Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum (II). Int J Cancer 47:252-260, 1991.
110. Cole SP, Downes HF, Mirsky SEL, et al: Alterations in glutathione and glutathione-related enzymes in a multi-drug resistant small cell lung cancer cell line. Mol Pharmacol 37:192-197, 1989.
111. Chen G, Zeller WJ : Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and -resistant rat ovarian tumors and its relation to DNA interstrand cross links. Anti-cancer Res 11:2231-2238, 1991.
112. O'Dwyer PJ, Hamilton TC, Young RC, et al: Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst 84:264-267, 1992.
113. Ploemen JH, van Ommen B, van Bladeren PJ: Inhibition of rat and human glutathione S-transferase isoenzymes by ethacrynic acid and its glutathione conjugate. Biochem Pharmacol 40:1631-1635, 1990.
114. Yamada T, Kaplowitz N: Binding of ethacrynic acid to hepatic glutathione S-transferases in vivo in the rat. Biochem Pharmacol 29:1205-1208, 1980.
115. Tew KD, Clapper ML: Glutathione S-transferases and anticancer drug resistance. In: Mechanisms of Drug Resistance in Neoplastic Cells, edited by PV Woolley, KD Tew, New York, Academic Press, 1988, pp 141-159.
116. Hansson J, Berhane K, Castro VM, et al: Sensitization of human melanoma cells to the cytotoxic effect of melphalan by the glutathione transferase inhibitor ethacrynic acid. Cancer Res 51:94-98, 1991.
117. Berhane K, Hoa X-Y, Egyhzi S, et al: Contribution of glutathione transferase M3-3 to 1,3-bis(2-chloroethyl)-1-nitrosourea resistance in a human non-small cell lung cancer cell line. Cancer Res 49:2621-2625, 1989.
118. Xu BH, Singh SV: Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogs BMY 25282 and BMY 25067. Cancer Res 52:6666-6670, 1992.
119. Nagoumey RA, Messenger JC, Kern DH, et al: Enhancement of anthracycline and alkylator cytotoxicity by ethacrynic acid in primary cultures of human tissues. Cancer Chemother Pharmacol 26:318-322, 1990.
120. O'Dwyer PJ, LaCreta F, Nash S, et al: Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res 51:6059-6065, 1991.
121. Petrini M, Conte A, Caracciolo F, et al: Reversing of chlorambucil resistance by ethacrynic acid in a B-CLL patient. Br J Haematol 85:409-410, 1993.
122. Lyttle MH, Hocker MD, Hui HC, et al : Isoenzyme-specific glutathione S-transferase inhibitors: Design and synthesis. J Med Chem 37:189-194, 1994.